Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 1703880 + Ezabenlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 1703880 | BI-1703880|BI1703880 | STING1 Agonist 19 | BI 1703880 acts as a STING agonist, potentially resulting in increased type 1 interferon response and cytokine release (Journal for ImmunoTherapy of Cancer 2022;10, Suppl_2, 626). | |
Ezabenlimab | BI754091|BI-754091|BI 754091 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 123 | Ezabenlimab (BI 754091) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05471856 | Phase I | BI 1703880 + Ezabenlimab | A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) | Recruiting | USA | GBR | ESP | 1 |